BioProcessing Asia is a biopharmaceutical science and technology focused Conference Series registered in Sweden as a non-profit Association. Organisation No: 802503-6792.
The Conference is dependent on the support of the biopharmaceutical industry. We are grateful to all of our sponsors, both past and present for helping to make BioProcessing Asia such a successful conference.
GE Healthcare Life Sciences is the principal sponsor.
GE Healthcare Life Sciences is helping life science researchers and biopharmaceutical manufacturers evolve how new therapies and precision medicines are discovered, made, and used. Our goal is to aid in providing the right treatment to the right patient in a cost-effective, efficient, and safe way – improving the quality of life for every person.
GE Healthcare Life Sciences comprises:
Cell & Gene Therapy
Genomics & Cellular Research
We draw on our heritage in biotechnology manufacturing and strength in infrastructure and service projects to help our customers establish global biomanufacturing capacity where disease demographics and population growth drive the greatest need.
Within the dynamic and evolving healthcare ecosystem, we are advancing and accelerating discovery, manufacturing, diagnostics, and most importantly, future therapeutics.
At Novo Nordisk we are driving change to defeat diabetes and other serious chronic diseases.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion at the end 2018 with a CORE EBITDA of CHF 1.5 billion.